Product Introduction
Bioactivity


英文名: IDX184

描述: IDX184 是一种有效的，具有口服活性的靶向 HCV 聚合酶抑制剂和核苷聚合酶抑制剂。IDX184 有效抑制 HCV 聚合酶 (IC50=0.31 μM，Ki=52.3 nM)。 IDX184是一种肝脏靶向核苷酸前药，具有抗HCV活性，可抑制HCV NS5B聚合酶，可与聚乙二醇化干扰素-α2a 和利巴韦林联合用于初治慢性丙型肝炎。

体外活性: IDX184, a liver-targeted prodrug of the nucleotide 2′-MeG-MP, serves as a hepatitis C virus polymerase inhibitor with liver-specific targeting.[1]IDX184 is not toxic (CC50>100μM) in any tested cell line.[2]IDX184 is a second-generation, orally bioavailable nucleotide prodrug designed to provide increased anti-HCV efficacy and safety versus the parent nucleoside. In HCV replicon testing, IDX184 is the most potent inhibitor (EC50=0.3-0.45 μM) compared to any of the 2’ or 4’ modified nucleosides (EC50=4-6 μM) and is also highly inhibitory in the JFH-1 infectious system (EC50=0.06-0.11 μM).[2]

存储条件: store at low temperaturePowder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: IDX184

相关产品: Letermovir | Azvudine | Telaprevir | Simeprevir | ITX5061 | Velpatasvir | Sofosbuvir impurity N | Lycorine hydrochloride | Danoprevir | Trachelogenin

相关库: Inhibitor Library